On October 23, 2025, Scienture Holdings, Inc. announced the start of commercial sales and the fulfillment of the first customer orders for its flagship product, Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL. The announcement confirms that the company has moved from development to execution, with the product now available for purchase by healthcare providers and institutions.
Arbli™ is the first FDA‑approved, ready‑to‑use oral suspension formulation of losartan potassium in the United States. The U.S. losartan market is estimated at $256 million in annual sales with more than 71 million prescriptions written each year, creating a sizable commercial opportunity for a liquid alternative that eliminates the need for compounding and offers a reduced dosing volume and a 24‑month shelf life at room temperature.
The company’s commercial strategy includes targeted outreach to healthcare professionals and the finalization of pharmacy benefit manager‑led group purchasing organization (PBM‑GPO) agreements that expand formulary access. In addition, Scienture has secured multiple GPO agreements covering over 2,500 healthcare institutions nationwide, representing an estimated 20 % penetration of the U.S. institutional market, including hospitals, clinics, nursing homes, specialty pharmacies, long‑term care facilities, and ambulatory centers.
Narasimhan Mani, President and co‑CEO of Scienture, said, “The start of commercial sales for Arbli™ represents a major achievement as we transition from development to execution. As promotional efforts expand and demand builds across retail, institutional and long‑term care markets, we see significant potential for sustained adoption and value creation.”
Shankar Hariharan, Executive Chairman and co‑CEO, added, “Arbli™ embodies our mission to deliver patient‑focused pharmaceutical solutions that improve access and convenience. We are encouraged by the early response from healthcare institutions and remain committed to expanding education, awareness, and availability of this first‑of‑its‑kind treatment option.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.